Jackson Center, PA, September 8, 2020 – Halberd Corporation (OTC PINK: “HALB“) today announced Arizona State University (ASU) commenced its research work for Halberd Corp. The initial phases of ASU’s research focuses on the development of antibodies in support of Halberd’s two issued patents and three Covid-19 related provisional patent applications for extracorporeal removal of the virus’ antigens from a patient’s blood.  Those antibodies could be multifaceted, including with regard to other viruses. The research will also focus on neutralizing the effects of antigens and developing one or more therapies.

William A. Hartman, Chairman, President and CEO of Halberd Corporation stated, “ASU has assembled an excellent team of very impressive scientists and researchers.  We have every confidence they can deliver the desired results.  We are particularly impressed with their focus on Phase 1 of the research.”

For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com;
support@halberdcorporation.com
www.halberdcorporation.com
P. O. Box 25
Jackson Center, PA 16133
Twitter:@HalberdC

About Arizona State University.

Arizona State University is a public research university with 5 campuses in and around Phoenix, with four regional centers throughout Arizona.  It is one of the largest public universities, based on enrollment, and one of the fastest growing research universities in the United States. The school boasts over 400 National Academies-honored faculty, and 77 elite programs.

About Halberd Corporation.

HalberdCorporation. (OTC-PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. It is debt-free and holds the exclusive rights to the COVID-19 extracorporeal treatment technology provisional patent applications: “Method for Treating and Curing Covid-19 Infection;” “Method for Treating COVID-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in COVID-19 Patients;” and “Method for Treating and Curing COVID-19 Infection by Utilizing a Laser to Eradicate the Virus.”  Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.

Title

Application No.

Filing Date

Priority

Status
Method for Treating and Curing Covid-19 Infection

US 62/989981

03/16/2020

n/a

Provisional application Pending
Method for Treating Covid-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in Covid-19 Patients

US 63/007207

04/08/2020

n/a

Provisional application Pending
Method for Treating and Curing Covid-19 Infection by Utilizing a Laser to Eradicate the Virus

US 63/013104

4/21/2020

n/a

Provisional application Pending

 

Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance.  Forward-looking statements are based on estimates and opinions of management at the time statements are made.  These statements may address issues that involve significant risks, uncertainties, estimates made by management.  Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.

Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives –
On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis.

The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment or other strategies with regard to COVID-19.

The ultimate impact of the COVID-19 pandemic on the Company’s operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.

We further caution investors that our primary focus and goal is to battle this pandemic for the good of the world. As such, it is possible that we may find it necessary to make disclosures which are consistent with that goal, but which may be adverse to the pecuniary interests of the Company and of its shareholders.